Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
Vončina L, Strbad T, Fürst J, Dimitrova M, Kamusheva M, Vila M, Mardare I, Hristova K, Harsanyi A, Atanasijević D, Banović I, Bobinac A. Vončina L, et al. Among authors: furst j. Appl Health Econ Health Policy. 2021 Nov;19(6):915-927. doi: 10.1007/s40258-021-00678-w. Epub 2021 Sep 23. Appl Health Econ Health Policy. 2021. PMID: 34553334 Review.
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.
Godman B, Malmström RE, Diogene E, Jayathissa S, McTaggart S, Cars T, Alvarez-Madrazo S, Baumgärtel C, Brzezinska A, Bucsics A, Campbell S, Eriksson I, Finlayson A, Fürst J, Garuoliene K, Gutiérrez-Ibarluzea I, Hviding K, Herholz H, Joppi R, Kalaba M, Laius O, Malinowska K, Pedersen HB, Markovic-Pekovic V, Piessnegger J, Selke G, Sermet C, Spillane S, Tomek D, Vončina L, Vlahović-Palčevski V, Wale J, Wladysiuk M, van Woerkom M, Zara C, Gustafsson LL. Godman B, et al. Among authors: furst j. Front Pharmacol. 2014 Jun 10;5:109. doi: 10.3389/fphar.2014.00109. eCollection 2014. Front Pharmacol. 2014. PMID: 24959145 Free PMC article. Review.
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.
Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, Bishop I, Bucsics A, Campbell S, Finlayson AE, Fürst J, Garuoliene K, Herholz H, Kalaba M, Laius O, Piessnegger J, Sermet C, Schwabe U, Vlahović-Palčevski VV, Markovic-Pekovic V, Vončina L, Malinowska K, Zara C, Gustafsson LL. Godman B, et al. Among authors: furst j. Front Pharmacol. 2014 Jun 17;5:106. doi: 10.3389/fphar.2014.00106. eCollection 2014. Front Pharmacol. 2014. PMID: 24987370 Free PMC article. Review.
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.
Ferrario A, Arāja D, Bochenek T, Čatić T, Dankó D, Dimitrova M, Fürst J, Greičiūtė-Kuprijanov I, Hoxha I, Jakupi A, Laidmäe E, Löblová O, Mardare I, Markovic-Pekovic V, Meshkov D, Novakovic T, Petrova G, Pomorski M, Tomek D, Voncina L, Haycox A, Kanavos P, Vella Bonanno P, Godman B. Ferrario A, et al. Among authors: furst j. Pharmacoeconomics. 2017 Dec;35(12):1271-1285. doi: 10.1007/s40273-017-0559-4. Pharmacoeconomics. 2017. PMID: 28836222 Free PMC article.
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.
Vella Bonanno P, Ermisch M, Godman B, Martin AP, Van Den Bergh J, Bezmelnitsyna L, Bucsics A, Arickx F, Bybau A, Bochenek T, van de Casteele M, Diogene E, Eriksson I, Fürst J, Gad M, Greičiūtė-Kuprijanov I, van der Graaff M, Gulbinovic J, Jones J, Joppi R, Kalaba M, Laius O, Langner I, Mardare I, Markovic-Pekovic V, Magnusson E, Melien O, Meshkov DO, Petrova GI, Selke G, Sermet C, Simoens S, Schuurman A, Ramos R, Rodrigues J, Zara C, Zebedin-Brandl E, Haycox A. Vella Bonanno P, et al. Among authors: furst j. Front Pharmacol. 2017 Aug 23;8:497. doi: 10.3389/fphar.2017.00497. eCollection 2017. Front Pharmacol. 2017. PMID: 28878667 Free PMC article. Review.
Policies for biosimilar uptake in Europe: An overview.
Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, Claus B, Dimitrova M, Petrova G, Sović-Brkičić L, Slabý J, Šebesta R, Laius O, Karr A, Beck M, Martikainen JE, Selke GW, Spillane S, McCullagh L, Trifirò G, Vella Bonanno P, Mack A, Fogele A, Viksna A, Władysiuk M, Mota-Filipe H, Meshkov D, Kalaba M, Mencej Bedrač S, Fürst J, Zara C, Skiöld P, Magnússon E, Simoens S. Moorkens E, et al. Among authors: furst j. PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017. PLoS One. 2017. PMID: 29284064 Free PMC article.
The European challenges of funding orphan medicinal products.
Szegedi M, Zelei T, Arickx F, Bucsics A, Cohn-Zanchetta E, Fürst J, Kamusheva M, Kawalec P, Petrova G, Slaby J, Stawowczyk E, Vocelka M, Zechmeister-Koss I, Kaló Z, Molnár MJ. Szegedi M, et al. Among authors: furst j. Orphanet J Rare Dis. 2018 Nov 6;13(1):184. doi: 10.1186/s13023-018-0927-y. Orphanet J Rare Dis. 2018. PMID: 30396361 Free PMC article.
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe CC, Ferrario A, Bosselli S, Hill A, Martin AP, Simoens S, Kurdi A, Gad M, Gulbinovič J, Timoney A, Bochenek T, Salem A, Hoxha I, Sauermann R, Massele A, Guerra AA Jr, Petrova G, Mitkova Z, Achniotou G, Laius O, Sermet C, Selke G, Kourafalos V, Yfantopoulos J, Magnusson E, Joppi R, Oluka M, Kwon HY, Jakupi A, Kalemeera F, Fadare JO, Melien O, Pomorski M, Wladysiuk M, Marković-Peković V, Mardare I, Meshkov D, Novakovic T, Fürst J, Tomek D, Zara C, Diogene E, Meyer JC, Malmström R, Wettermark B, Matsebula Z, Campbell S, Haycox A. Godman B, et al. Among authors: furst j. Front Public Health. 2018 Dec 5;6:328. doi: 10.3389/fpubh.2018.00328. eCollection 2018. Front Public Health. 2018. PMID: 30568938 Free PMC article. Review.
Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA.
Vella Bonanno P, Bucsics A, Simoens S, Martin AP, Oortwijn W, Gulbinovič J, Rothe C, Timoney A, Ferrario A, Gad M, Salem A, Hoxha I, Sauermann R, Kamusheva M, Dimitrova M, Petrova G, Laius O, Selke G, Kourafalos V, Yfantopoulos J, Magnusson E, Joppi R, Jakupi A, Bochenek T, Wladysiuk M, Furtado C, Marković-Peković V, Mardare I, Meshkov D, Fürst J, Tomek D, Cortadellas MO, Zara C, Haycox A, Campbell S, Godman B. Vella Bonanno P, et al. Among authors: furst j. Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):251-261. doi: 10.1080/14737167.2019.1575730. Epub 2019 Feb 15. Expert Rev Pharmacoecon Outcomes Res. 2019. PMID: 30696372 Free article.
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.
Pontes C, Zara C, Torrent-Farnell J, Obach M, Nadal C, Vella-Bonanno P, Ermisch M, Simoens S, Hauegen RC, Gulbinovic J, Timoney A, Martin AP, Mueller T, Nachtnebel A, Campbell S, Selke G, Bochenek T, Rothe CC, Mardare I, Bennie M, Fürst J, Malmstrom RE, Godman B. Pontes C, et al. Among authors: furst j. Appl Health Econ Health Policy. 2020 Feb;18(1):5-16. doi: 10.1007/s40258-019-00527-x. Appl Health Econ Health Policy. 2020. PMID: 31696433 Free article.
227 results